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Abstract
Background Dopamine D3 receptors regulate sensorimotor
gating in rats, as evidenced by changes in prepulse
inhibition (PPI) of startle after acute administration of D3
agonists and antagonists. In this study, we tested the effects
of the D3-preferential agonist, pramipexole, on PPI in
normal men and Sprague–Dawley rats.
Materials and Methods Acoustic startle and PPI were
tested in clinically normal men, comparing the effects of
placebo vs. 0.125 mg (n=20) or placebo vs. 0.1875 mg (n=
20) pramipexole, in double blind, crossover designs. These
measures were also tested in male Sprague–Dawley rats
using a parallel design [vehicle vs. 0.1 mg/kg (n=8),
vehicle vs. 0.3 mg/kg (n=8) or vehicle vs. 1.0 mg/kg
pramipexole (n=8)]. Autonomic and subjective measures of
pramipexole effects and several personality instruments
were also measured in humans.
Results Pramipexole increased drowsiness and significantly
increased PPI at 120-ms intervals in humans; the latter
effect was not moderated by baseline PPI or personality
scale scores. In rats, pramipexole causes a dose-dependent
reduction in long-interval (120 ms) PPI, while low doses
actually increased short-interval (10–20 ms) PPI. Effects of
pramipexole on PPI in rats were independent of baseline
PPI and changes in startle magnitude.
Conclusion The preferential D3 agonist pramipexole modi-
fies PPI in humans and rats. Unlike indirect DA agonists
and mixed D2/D3 agonists, pramipexole increases long-
interval PPI in humans, in a manner that is independent of
baseline PPI and personality measures. These findings are
consistent with preclinical evidence for differences in the
D2- and D3-mediated regulation of sensorimotor gating.
Keywords Dopamine.Prepulseinhibition.Pramipexole.
Sensorimotorgating.Startle
Introduction
Prepulse inhibition (PPI) is an operational measure of
sensorimotor gating, in which a startle response to an
intense stimulus is automatically suppressed by a weak lead
stimulus (Graham 1975). In humans, PPI is typically
assessed using electromyographic measures of the blink
response, while in rodents, PPI is typically assessed by
measuring whole-body startle. PPI deficits are found in
several neuropsychiatric disorders (Braff et al. 1978; cf.
Braff et al. 2001; cf. Swerdlow et al. 2008), and the biology
of these deficits has been the focus of intense study in
humans and animal models.
In rats, dopamine (DA) agonists generally reduce PPI,
although these effects are highlystrain-sensitive (Swerdlow et
al. 2004b). For example, the mixed D1/D2 agonist apomor-
phine (APO) disrupts PPI in albino Sprague–Dawley rats but
not in pigmented ACI rats, while in hooded Long Evans rats,
APO increases PPI at short prepulse intervals and reduces it
at long prepulse intervals (Swerdlow et al. 2004a, b). In
humans, the effects of DA agonists on PPI differ across
groups distinguished by baseline PPI levels and/or person-
ality dimensions. For example, Bitsios et al. (2005)r e p o r t e d
PPI-disruptive effects of the DA agonists pergolide and
amantadine only among men characterized by high baseline
PPI levels, Giakoumaki et al. (2007) reported a reduction in
PPI after administration of the mixed D2/D3 agonist
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and we reported similar baseline-dependent effects of
amphetamine on PPI in healthy men (Swerdlow et al.
2003b) and women (Talledo et al. 2009). Furthermore,
amphetamine has been reported to disrupt PPI only among
normal subjects with high scores on measures of novelty- or
sensation-seeking (Hutchison et al. 1999; Talledo et al.
2009). In some subgroups of normal humans (e.g., those
characterized by low baseline PPI or novelty seeking), DA
agonists can actually increase PPI (Talledo et al. 2009).
Some evidence suggests that differences in PPI sensitivity to
DA agonists in rats and humans may be mediated in part by
differences in brain regional activity of catechol-O-methyl
transferase (Shilling et al. 2008; Roussos et al. 2008b;
Talledo et al. 2009).
The present study tested the effects of pramipexole, a
non-ergot preferential D3 agonist, on PPI. While the vast
majority of studies of the DAergic regulation of PPI in rats
and humans focus on the role of D1 and D2 receptors, more
recent evidence suggests that PPI in both species may also
be regulated by D3 receptors. For example, Roussos et al.
(2008a) reported that PPI differed significantly across
humans characterized by Gly/Gly vs. Ser/Ser variants of
the D3 receptor Ser9Gly polymorphism. Pramipexole has
preferential affinity for D3 vs. D2 receptors, with an in vitro
D3/D2 preference of 7.8:1 (Piercey et al. 1996, Svensson et
al. 1994; cf. Kvernmo et al. 2006) relative to the high
affinity state of the D2 receptor. Millan et al. (2002)
determined the D3/D2 preference of pramipexole to be 90:1
relative to the short isoform of the human receptor (D2S)
and 160:1 relative to the long isoform (D2L). In compar-
ison, ropinirole is relatively less preferential for D3
receptors [e.g., in vitro D3/D2 preference=1.3:1 (cf.
Kvernmo et al. 2006), with preference of 18:1 relative to
D2S and 25:1 relative to D2L (Millan et al. 2002)].
Our group reported that pramipexole disrupts PPI in
laboratory rats and that this effect is relatively insensitive to
selective D2 blockade but is opposed by functional D3
antagonists (Weber et al. 2008, 2009). In addition, strain
differences in the PPI-disruptive effects of indirect DA
agonists (amphetamine, Swerdlow et al. 2003a), mixed D1/
D2 agonists (APO, Swerdlow et al. 2001), and D2-
preferential agonists (quinpirole, Swerdlow et al. 2001)
are not detected with pramipexole (Weber et al. 2008),
suggesting that its PPI-disruptive effects are mediated
differently from those of non-D3 DA agonists. In this
study, we examined the effects of pramipexole on PPI in
normal men, also assessing the potential moderating impact
of baseline PPI and personality scale scores.
Materials and methods
Human testing The methods used in these studies were
very similar to those used in studies described in recent
reports (Swerdlow et al. 2003b), were approved by the
UCSD Human Subjects Institutional Review Board, and
were approved and supported by the National Institute of
Mental Health. Forty right-handed men (Table 1) completed
testing; the study involved a phone contact and three
laboratory visits. Phone screening procedures were identical
to those described in previous reports from our group
(Swerdlow et al. 2003b).
After passing a telephone interview, subjects came to the
laboratory for a screening examination, during which the
senior investigator (NRS) informed subjects of the potential
risks and benefits of the study. Subjects read and signed a
consent form for study participation, underwent a physical
examination and electrocardiogram to rule out exclusionary
Table 1 Subject characteristics
Subject characteristics 0.125 mg dose 0.1875 mg dose
Age (mean (range), years) 21.9 (18–30) 22.5 (18.0–33.0)
Weight (mean (range), kg) 76.8 (59.4–122.5) 72.3 (56.7–89.8)
Dose PRAM (mean (range), mg/kg x 10
3) 1.67 (1.02–2.10) 2.63 (2.08–3.30)
Daily caffeine intake (mean (range), mg) 138.5 (0.0-615.2) 62.3 (0.0–280.0)
Personality scale scores (mean (range))
TPQ
Novelty seeking 17 (8–23) 15 (4–25)
Harm avoidance 8 (0–19) 8 (0–18)
Reward dependence 19 (9–27) 19 (10–26)
SSS
Total score 21 (10–28) 20 (8–31)
EPQ
Total score 21 (9–29) 20 (7–32)
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for DSM disorders (non-patient edition; SCID; First et al.
1997) to rule out Axis I diagnoses, and completed a urine
toxicology test with exclusion for any illicit drug. Audi-
ometry confirmed hearing threshold <40 dB(A) at
1,000 Hz. Subjects also completed a limited test of the
acoustic startle reflex to screen for a minimum eyeblink
startle magnitude of 50 units (1.22 µV/unit) using 118 dB
(A), 40 ms noise pulses.
Subjects completed the following questionnaires: (1) the
Tridimensional Personality Questionnaire (TPQ; Cloninger
1987) to assess the relationship between novelty-seeking
scores (NS) and sensitivity to the effects of pramipexole on
PPI, based on reports that high NS individuals are most
sensitive to the PPI-disruptive effects of indirect DA
agonists (Hutchison et al. 1999; Talledo et al. 2009) and
the PPI-enhancing effects of antipsychotics (Swerdlow et
al. 2006); (2) the Sensation Seeking Scale (SSS; Zuckerman
et al. 1972), based on reported increased sensitivity to DA
agonists in individuals scoring high on this measure
(Hutchison et al. 1999); and (3) the Eysenck Personality
Questionnaire (EPQ) (Eysenck and Eysenck 1994). Sub-
jects who passed screening criteria were tested 6–8 days
later and retested 6–8 days after their first experimental
session.
The study had a two-test within-subject design for each
dose of pramipexole. In other words, one group of subjects
(n=20) was tested with placebo and 0.125 mg pramipexole,
and a second group of subjects (n=20) was tested with
placebo and 0.1875 mg pramipexole. On test days, subjects
arrived at 0830 hours and ate a standardized breakfast, and
pramipexole (0.125 or 0.1875 mg; Boehringer Ingelheim
GmbH, Ingelheim, Germany) or placebo was administered
at 0930 hours. Startle testing began 60 min after pill
administration. Heart rate and blood pressure were deter-
mined (sitting position and brachial cuff), and subjects
completed a symptom rating scale every 30–45 min; the
first one occurred before pill ingestion. Symptom-rating
visual analog scales (VAS) were designed to assess general
somatic and psychological symptoms and level of con-
sciousness (modified from Norris 1971; Bond and Lader
1974; Bunney et al. 1999). Subjects made a single, vertical
mark representing their current state along a 100-mm line
(0 mm represents “not true” and 100 mm represents “true”).
Ratings assessed several states: “happy,”“ queasy,”“ dizzy,”
“drowsy,” and perceptual sensitivity. Details of these rating
scales are found in Swerdlow et al. (2002) and included
prompts such as “Normal sounds seem unusually intense
or loud.”
For startle testing, subjects sat upright and were directed
to look straight ahead and to stay awake. Two miniature
Ag/AgCl electrodes were positioned below and to the outer
canthus of each eye over orbicularis oculi; ground electrode
was positioned behind the left ear (R<10 kΩ). Electromyo-
graphic activity was band-pass-filtered (1–1,000 Hz) and
60-Hz notch-filtered, and digitized, and 250 1-ms readings
were recorded starting at startle stimulus onset. Acoustic
startle stimuli were delivered by Telephonics (TDH-39-P,
Maico) headphones. A background 70 dB(A) white noise
was continuous throughout the session. Test sessions began
with a 3-min acclimation period; during this period, the
number of spontaneous eyeblinks were counted by a remote
observer using a RadioShack security camera system
(model 49-2513) (inter-observer R=0.97). This was fol-
lowed by 42 trials with six conditions repeated in
pseudorandom order: a 118-dB(A), 40-ms noise burst alone
(pulse alone) and the same 118-dB(A), 40-ms noise burst
preceded 10, 20, 30, 60, or 120 ms by a prepulse (5-ms
burst) 16 dB over background. Avariable inter-trial interval
averaged 20 s (15–25 s). The test session was structured
identically to that described in our previous studies of DA
agonist effects on PPI in humans (Swerdlow et al. 2003b;
Talledo et al. 2009). On completion of this startle test,
additional autonomic and subjective rating measurements
were obtained, as were additional “pilot” psychophysiolog-
ical measures, including a visual latent inhibition task. Data
from these subsequent tests are not included in this
analysis.
The primary reasons for disqualification were that
subjects had low screening startle magnitude (n=22),
withdrew from testing prior to the second test day (n=3),
or had a SCID-based diagnosis (n=14; First et al. 1997);
others included positive urine toxicology for illicit drugs
(n=2).
PPI was defined as [100-(100 × magnitude on prepulse
trial/magnitude on pulse alone trial)]. Screening PPI across
all 40 subjects was normally distributed [mean (SD)%
across all intervals (10–120 ms)=9.33 (20.25); median=
7.68; skewness=0.27; kurtosis=0.17]. Startle magnitude,
latency, and PPI were analyzed with mixed-design analyses
of variance (ANOVAs), with trial type and pramipexole
dose (placebo vs. active) as within-subject factors, and dose
groups [i.e., subjects tested with placebo vs. 0.125 mg
pramipexole (“0.125 mg group”) and subjects tested with
placebo vs. 0.1875 mg pramipexole (“0.1875 mg group”)]
as the between-subject factor. Separate analyses were then
pursued on each dose group. No consistent drug interac-
tions were noted with eye side (left vs. right), and thus,
main effects of eye side and interactions are not reported.
“Baseline PPI” was defined as the mean %PPI for 60- and
120-ms prepulse intervals on the screening day, as
described previously (Swerdlow et al. 2009). Personality
scales previously found to be related to drug effects on PPI
were treated as continuous variables: the total novelty-
seeking score (NS) from the TPQ, total and disinhibition
subscale scores from the SSS, and extraversion subscale
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were treated as continuous variables and were analyzed
with mixed-design ANOVAs, focusing on difference scores
(change from pre-pill baseline to time of PPI testing).
Specific post-hoc comparisons were made with one-factor
ANOVAs or the Fisher’s protected least significant differ-
ence test. Alpha was 0.05. In most cases, post-hoc
comparisons were limited to tests of specific a priori
hypotheses (e.g., that DA agonist effects on PPI would be
dependent on baseline PPI) or planned comparisons (e.g.,
relationship of PPI pramipexole sensitivity to personality
measures).
Rodent testing The methods used in this study were in
accordance with the National Institute of Health Guide for the
Care and Use of Laboratory Animals (NIH Publications no.
80-23) and approved by the UCSD Animal Subjects
Committee (protocol S01221). Adult male Sprague–Dawley
rats (225–250 g; Harlan Laboratories, San Diego, CA, USA)
were housed in groups of two to three animals per cage and
maintained on a reversed light/dark schedule with water and
food available ad libitum. Rats were handled within 2 days of
arrival. Testing occurred during the dark phase. Pramipexole
(Toronto Research Chemicals, North York, Ontario, Canada)
was dissolved in saline vehicle and administered subcutane-
ouslyindosesof0or0.1mg/kg(n=8),0or0.3mg/kg(n=8),
or 0 or 1.0 mg/kg (n=8), with the same parallel within-
subject dose design used in humans (doses from Weber et al.
2008). Startle chambers (San Diego Instruments, San Diego,
CA, USA) were housed in a sound-attenuated room and
consisted of a Plexiglas cylinder 8.2 cm in diameter resting
on a 12.5×25.5 cm Plexiglas frame within a ventilated
enclosure. Noise bursts were presented via a speaker
mounted 24 cm above the cylinder. A piezoelectric acceler-
ometer mounted below the Plexiglas frame detected and
transduced motion from within the cylinder. Stimulus
delivery was controlled by the SR-LAB microcomputer and
interface assembly, which also digitized (0–4095), rectified,
and recorded stabilimeter readings. One hundred 1-ms
readings were collected beginning at stimulus onset. Startle
amplitude was defined as the average of the 100 readings.
Approximately 7 days after shipment arrival, rats were
exposed to a short “matching” startle session. They were
placed in the startle chambers for a 5-min acclimation
period with a 70 dB(A) background noise and then exposed
to a total of 17 P-alone trials (40 ms–120 dB(A) noise
bursts) that were interspersed with three PP12dB+P-alone
trials [P-alone preceded 100 ms (onset-to-onset) by a 20-ms
noise burst of 12dB above background]. Rats were assigned
to dose order groups based on average %PPI from the
matching session to ensure similar baseline PPI levels
between groups. Four days later, rats were injected with
pramipexole (vehicle or active dose) and, 15 min later,
placed in the startle chambers for a 5-min acclimation
period with a 70-dB(A) background noise. They were then
exposed to a series of trial types within a test session
identical to that used in testing humans (see above, “Human
testing”). Three days later, testing was repeated, with
pramipexole dose reversed. Statistical analyses of startle
magnitude and PPI were structured identically to those used
in humans.
Results
Human testing
Demographic variables and personality scale scores for all
subjects are seen in Table 1.
Effects of pramipexole on autonomic and self-rating
measures are seen in Fig. 1 and Table 2. The only robust
evidence of bioactivity of these doses of pramipexole came
in significant increases in self-rated “drowsiness” (Fig. 1).
ANOVA of the change in ratings from pre-pill baselines for
all subjects revealed a significant effect of pramipexole (F=
8.16, df 1,38, p<0.007), no significant effect of dose group
(F<1), and no significant interaction of pramipexole×dose
group (F=1.04). Analysis limited to 0.125 mg pramipexole
revealed no significant effect of pramipexole on drowsiness
(F=2.94, df 1,19, ns), while analysis limited to 0.1875 mg
pramipexole revealed a significant increase in drowsiness at
the time of PPI testing [mean (SEM) increase in VAS after
pramipexole=23.6 (6.02) vs. placebo=5.05 (5.50); F=5.27,
df 1,19, p<0.035]. In contrast, no significant effects of
pramipexole were detected for either dose in measures of
Fig. 1 Self-rated drowsiness VAS scores after placebo (open circles),
0.125 mg or 0.1875 mg pramipexole (closed circles), compared to pre-
pill baselines (mean±SEM). Time of PPI testing is indicated by arrow.
Number sign Significantly greater increase in drowsiness at time of
PPI testing, pramipexole vs. placebo (p<0.007) by ANOVA; post-hoc
individual comparisons detected significant effects only for the
0.1875 mg dose (p<0.035)
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or spontaneous blink rate or in self-rated measures of
dizziness, queasiness, happiness, or sensory sensitivity
(Table 2).
Pramipexole tended to diminish startle magnitude on
pulse trials, but this effect did not reach statistical
significance. Across all subjects, ANOVA of startle
magnitude on all trial types revealed no significant main
effect of pramipexole (F=2.94, df 1,38, 0.10>p>0.05) or
dose group (F<1), and no pramipexole×dose group
interaction (F=2.12, df 1,38, ns). There was a significant
effect of trial type (reflecting the startle-reducing effects of
prepulses: F=33.14, df 5,190, p<0.0001), but no other
significant two- or three-way interactions. Inspection of
t h ed a t a( F i g .2) suggested no effect of 0.125 mg
pramipexole on startle magnitude, and this was confirmed
by ANOVA (placebo vs. 0.125 mg, F<1; main effect of
trial type, F=15.42, df 5,95, p<0.0001; no significant
Table 2 Autonomic and subjective effects of pramipexole (mean (SEM))
Min
post-pill
Heart rate
(BPM)
BP
systolic
(mm)
BP
diastolic
(mm)
Queasy
(VAS)
Dizzy
(VAS)
Cannot
focus
(VAS)
Sounds
loud
(VAS)
Happy
(VAS)
Pupil
a
(mm)
Temp
b
(°F)
0.125 mg group
0
c 68.6 (1.4) 116.4 (1.7) 69.3 (1.5) 2.6 (1.0) 2.8 (1.2) 6.6 (3.5) 2.2 (0.9) 67.6 (6.0) 5.4 (0.2) 97.3 (0.1)
Change after
placebo
15 0.6 (0.8) −1.3 (1.1) −0.7 (0.7) 0.6 (1.1) 1.4 (1.0) 0.9 (0.8) 1.1 (0.7) −1.1 (1.8) ––
80 1.6 (1.1) −1.6 (1.8) 1.8 (1.1) 1.8 (1.7) 3.4 (1.6) 1.2 (1.0) 1.0 (1.0) −3.0 (2.1) ––
110 2.6 (1.1) −2.3 (1.6) 1.4 (1.3) 1.4 (1.5) 1.6 (1.7) 1.6 (0.9) 1.4 (1.4) −4.8 (2.9) ––
140 1.6 (1.1) −3.0 (1.6) 1.0 (1.2) 1.2 (1.6) 2.3 (2.5) 0.1 (1.3) 0.8 (0.7) −0.8 (2.2) 0.0 (0.2) 0.1 (0.1)
220 0.4 (1.3) −1.5 (1.7) −1.7 (1.6) −0.7 (1.1) −0.6 (1.0) 1.8 (2.6) 1.1 (1.0) −3.4 (2.7) ––
255 1.4 (1.5) −0.6 (1.6) −0.7 (1.7) −0.7 (1.2) −0.2 (1.2) 0.6 (1.4) 0.8 (0.6) −4.2 (3.4) ––
445 –– ––––––0.3 (0.1) 0.4 (0.1)
0 67.4 (1.5) 114.1 (1.7) 69.0 (1.6) 2.0 (0.7) 2.6 (0.9 6.5 (3.0) 2.7 (1.0) 64.4 (6.5) 5.2 (0.2) 97.3 (0.1)
Change after
active dose
15 1.9 (0.9) −1.6 (0.6) −2.6 (0.9) 0.4 (0.5) 1.1 (1.1) 0.1 (1.6) 0.5 (0.6) 2.9 (2.4) ––
80 1.8 (1.1) −2.3 (0.9) −0.6 (1.1) 1.5 (1.0) 1.7 (1.2) 1.1 (1.8) 5.0 (3.2) −3.3 (3.4) ––
110 0.8 (1.3) −2.6 (0.9) −0.3 (1.3) 1.9 (1.4) 4.8 (2.9) 0.7 (2.1) 1.8 (1.3) −1.8 (4.4) ––
140 1.0 (1.2) −3.6 (1.1) −1.0 (1.3) 1.3 (0.9) 2.1 (1.2) 1.1 (2.0) 1.2 (1.0) −4.7 (3.2) 0.4 (0.2) 0.3 (0.1)
220 3.8 (1.2) 0.3 (1.0) −0.1 (1.2) 0.6 (0.6) 0.5 (0.6) 0.7 (2.0) 0.8 (1.0) −0.7 (4.4) ––
255 3.4 (1.2) 0.1 (1.0) −1.1 (1.3) 1.2 (0.9) 0.4 (0.5) −0.1 (1.7) 0.3 (0.6) 0.5 (3.6) ––
445 –– ––––––0.7 (0.2) 0.4 (0.2)
0.1875 mg group
0 65.6 (2.3) 112.9 (2.6) 64.7 (1.4) 1.9 (0.8) 1.5 (0.4) 1.2 (0.4) 5.8 (3.5) 87.9 (3.7) 5.5 (0.2) 97.5 (0.1)
Change after
placebo
15 2.8 (1.4) −0.9 (1.0) 0.1 (1.2) −0.2 (0.6) 4.9 (4.9) 0.2 (0.2) −2.0 (1.3) −1.4 (1.6) ––
80 2.8 (1.5) 0.3 (1.2 1.3 (1.5) −0.7 (0.8 4.2 (3.6 −0.1 (0.3) −2.0 (1.1 −5.3 (2.5) ––
110 3.2 (1.4) 0.2 (1.2) 1.8 (1.1) −0.2 (0.2) 3.2 (2.9) −0.2 (0.3) −2.2 (1.3) −4.8 (2.7) ––
140 2.0 (1.8) −0.1 (1.0) 2.5 (1.0) −0.6 (0.7) 3.1 (3.3) 0.2 (0.3) −1.7 (1.4) −4.0 (2.7) 0.3 (0.2) 0.2 (0.2)
220 2.6 (1.8) 0.6 (1.5) 2.3 (1.2) −0.9 (0.6) 3.6 (4.0) 0.2 (0.3) −2.1 (1.7) −2.8 (3.1) ––
255 2.6 (1.7) 0.2 (1.6) 1.5 (1.3) −0.9 (0.6) 4.8 (4.9) 0.6 (0.3) −2.3 (2.0) −3.3 (3.6) ––
445 –– ––––––−0.3 (0.2) 0.4 (0.1)
0 66.2 (1.7) 111.5 (2.4) 64.1 (1.6) 1.4 (0.3) 1.6 (0.6) 1.6 (0.4) 3.6 (2.3) 89.1 (4.1) 5.7 (0.3) 97.6 (0.2)
Change after
active dose
15 3.0 (1.0) 0.2 (1.6) 0.8 (1.8) 0.6 (0.3) 1.4 (0.9) 1.1 (0.7) 0.8 (0.7) 0.2 (1.2) ––
80 3.0 (1.4) −1.6 (1.3) 1.8 (1.6) 0.1 (0.4) 1.8 (1.3) 0.1 (0.5) 0.9 (0.5) 0.0 (1.3) ––
110 3.2 (1.4) −1.0 (1.6) 1.9 (1.9) 0.2 (0.3) 0.8 (0.5) −0.4 (0.5) 1.1 (0.7) −4.5 (2.1) ––
140 1.6 (1.1) −0.8 (1.6) 3.4 (2.1) 0.6 (0.4) 3.0 (2.5) −0.2 (0.4) 0.6 (0.7) −3.4 (2.1) 0.2 (0.3) 0.2 (0.1)
220 4.2 (1.2) 1.7 (2.1) 1.0 (1.4) 0.2 (0.4) 3.1 (2.6) −0.5 (0.4) −0.2 (0.5) −3.5 (2.4) ––
255 3.9 (1.7) 4.2 (2.4) 4.5 (1.6) 0.5 (0.6) 4.4 (3.9) −0.1 (0.3) −2.0 (2.4) −1.4 (2.3) ––
445 –– ––––––−0.3 (0.3) 0.3 (0.2)
aDiameter
bOral temperature
cPre-pill baseline
Psychopharmacology (2009) 205:689–698 693two-way interactions). However, 0.1875 mg pramipexole
did appear to reduce startle magnitude, and this was also
confirmed by ANOVA (placebo vs. 0.1875 mg, F=5.40,
df 1,19, p=0.005; main effect of trial, F=18.32, df 5,95, p
<0.0001). The interaction of dose×trial type was also
significant (F=2.43, df 5,95, p<0.045), suggesting differ-
ent effects of pramipexole on startle magnitude across the
different trial types. Post hoc comparisons revealed that
pramipexole did not significantly reduce startle magnitude
on pulse-alone trials (F=2.06, df 1,19, ns), but did
significantly reduce startle magnitude on 120-ms prepulse
trials (F=11.97, df 1,19, p<0.003; Fig. 2a). To examine
the independence of pramipexole effects on pulse alone
vs. 120-ms prepulse trials, a subgroup of 17 subjects was
created by eliminating three subjects whose pulse-alone
startle magnitude was most reduced by pramipexole. In
this way, the remaining group (n=17) exhibited absolutely
no startle-reducing effects of pramipexole on pulse-alone
trials [F<<1; mean (SEM) startle magnitude placebo vs.
0.1875 mg pramipexole=117.20 (15.90) vs. 116.04
(17.75)] but nonetheless exhibited significant startle-
reducing effects of pramipexole on 120-ms prepulse trials
(F=8.46, df 1,16, p=0.01; Fig. 3a).
Consistent with the selective startle-reducing effects of
pramipexole on 120-ms prepulse trials, pramipexole
significantly increased PPI at 120-ms intervals (Fig. 2b).
Across all subjects, ANOVA revealed no main effect of
pramipexole (F<1) or dose group (F<1) and no prami-
pexole×dose group interaction (F<1). There was a
significant effect of trial type (F=51.76, df 4,152, p<
0.0001) and a significant interaction of pramipexole×dose
group×trial type (F=2.53, df 4,152, p<0.05). Post hoc
comparisons revealed significant PPI-enhancing effects of
pramipexole on 120-ms prepulse trials (main effect of
pramipexole, F=4.12, df 1,38, p<0.05). This effect did
not differ by dose group (F<1) nor was there an
interaction of pramipexole×dose group (F<1), though
Fig. 3 Effects of pramipexole on startle magnitude (mean±SEM) (a)
and %PPI (mean±SEM) (b) across all trial conditions in a subgroup of
subjects treated with placebo vs. 0.1875 mg pramipexole (n=17) in
whom pramipexole caused no change in pulse alone startle magnitude.
Open circle Placebo; closed circle active dose. Asterisk Startle
reducing effects of pramipexole on prepulse+pulse trials at 120 ms
prepulse intervals (p=0.01); number sign PPI-enhancing effects of
pramipexole at 120-ms prepulse intervals (p=0.005)
Fig. 2 Effects of pramipexole on startle magnitude (mean±SEM) (a)
and %PPI (mean±SEM) (b) across all trial conditions in groups
treated with placebo vs. 0.125 mg pramipexole (n=20) or placebo vs.
0.1875 mg pramipexole (n=20). Open circle Placebo; closed circle
active dose. Asterisk Startle-reducing effects of 0.1875 mg pramipex-
ole on prepulse+pulse trials at 120-ms prepulse intervals (p<0.003);
number sign PPI-enhancing effects of pramipexole at 120-ms prepulse
intervals (p<0.05)
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more robust than those of 0.125 mg (d=0.48vs.0.20).We
examined whether the PPI-enhancing effects of 0.1875 mg
pramipexole were independent of the modest startle-
reducing effects of this dose on pulse-alone trials, using
the same subgroup of 17 subjects (described above) for
whom this dose of pramipexole did not reduce pulse-alone
startle magnitude. The PPI-enhancing effects of
0.1875 mg pramipexole were highly significant in this
subgroup (F=10.53, df 1,16, p=0.005; d=0.79; Fig. 3b).
Thus, pramipexole increased PPI at 120-mg prepulse
intervals, particularly at the 0.1875 mg dose, and this
effect was independent of changes in pulse-alone startle
magnitude.
Spearman rank correlations assessed relationships be-
tween the PPI-enhancing effects of 0.1875 mg pramipexole
at 120-ms prepulse intervals [calculated as a difference
score: PPI (pramipexole) minus PPI (placebo)] and scores
for novelty-seeking (TPQ total NS scale), sensation-seeking
(SSS total score and DIS subscale score), and extraversion
(EPQ-E subscale score). No correlations approached statis-
tical significance (−0.27<Rs<0.05). Simple regression
analyses revealed no correlation between these PPI-
enhancing effects of pramipexole at 120-ms prepulse
intervals and baseline startle magnitude (r=0.02) or the
impact of pramipexole on drowsiness (r=0.03).
Pramipexole had no significant effects on startle latency,
latency facilitation (reduction in latency caused by pre-
pulses), or habituation (Table 3).
Rodent testing
The highest dose of pramipexole (1.0 mg/kg) reduced
startle magnitude on pulse-alone trials (Fig. 4a). ANOVA of
startle magnitude across all dose groups revealed no
significant effect of group (F<1), a significant effect of
pramipexole dose (vehicle vs. active dose; F=10.91, df
1,21, p<0.004), and no interaction of group×dose (F=1.45,
df, 2,21, ns). Post-hoc comparison revealed significant
startle-reducing effects limited to the 1.0 mg/kg group (p<
0.035).
Pramipexole had dose- and interval-dependent effects on
PPI in rats (Fig. 4b). ANOVA across all groups revealed
near significant effects of group (F=3.32, df 2,21, p<0.056)
and dose (F=3.28, df 1,21, p<0.085), a near-significant
interaction of group×dose (F=3.24, df 2,21, p<0.06),
significant effects of prepulse interval (F=25.70, df 4,84,
p<0.0001), and a significant interaction of dose×interval
(F=3.60, df 4,84, p<0.01), but no significant three-way
interaction. In three rats from the high-dose group, mean
startle values on prepulse+pulse trials for some prepulse
intervals greatly exceeded startle values on pulse alone
trials, yielding large negative values for %PPI (i.e., prepulse
potentiation) and thus accounting for the large error bars
demonstrated in Fig. 4b; capping these values (e.g., at
−100%) did not alter the statistical outcome. Inspection of
the data revealed dose-dependent PPI-reducing effects of
pramipexole at the 120-ms prepulse interval and PPI-
increasing effects of lower doses of pramipexole at short
(10–20 ms) prepulse intervals. Post-hoc comparisons for
the 120-ms prepulse interval revealed significant effects of
group (F=4.15, df 2,21, p<0.035) and dose (F=15.04, df
1,21, p<0.001) and a significant group×dose interaction
(F=3.45, df 2,21, p=0.05). Pramipexole significantly
reduced 120 ms PPI at the 0.3 and 1.0 mg/kg doses (p<
0.008 and 0.03, respectively) but not at the 0.1 mg/kg dose.
Post-hoc comparisons for the 10–20-ms intervals revealed
significant PPI-increasing effects of the 0.1 and 0.3 mg/kg
doses (main effect of dose, F=6.81, df 1,14, p=0.02; no
effect of group, F<1; no dose×group interaction, F<1).
While significant PPI-reducing and PPI-increasing
effects of pramipexole were detected at doses that did not
significantly reduce startle magnitude on pulse alone trials,
we nonetheless examined whether drug effects on startle
magnitude and PPI could be more completely dissociated.
This was done in two ways. First, difference scores (vehicle
minus active dose) were calculated for pramipexole effects
on pulse-alone startle magnitude for each rat, and median
splits were used to divide each dose group into rats with the
least vs. most startle-reducing effects of pramipexole. Using
this median split as a grouping factor, ANOVAs confirmed
both the PPI-reducing effects of 0.3 and 1.0 mg/kg doses at
120-ms prepulse intervals and PPI-enhancing effects of 0.1
and 0.3 mg/kg doses at 10–20-ms intervals, with no
significant interactions of dose×median splits (all F’s<
1.75, 1, 1, and 1, respectively). Next, simple regression
analyses revealed no significant correlations between startle
magnitude difference scores (i.e., the effect of pramipexole
on startle magnitude) and PPI difference scores (i.e., the
effect of pramipexole on PPI) at either the short (10–20 ms)
or long (120 ms) prepulse intervals (r’s<0.30, ns).
Lastly, we examined the potential relationship between
baseline PPI (during the dose-matching session) and
pramipexole effects on PPI. Baseline PPI did not correlate
significantly with the effect of pramipexole on PPI at either
the short (10–20 ms) or long (120 ms) prepulse intervals
(r’s<0.18, ns).
Discussion
In the present study, pramipexole, a D3-preferential agonist,
increased long interval PPI in clinically normal men, and
had biphasic dose effects on PPI in rats—increasing short
interval PPI at low doses and decreasing long interval PPI
at higher doses. Unlike the PPI-enhancing or reducing
Psychopharmacology (2009) 205:689–698 695effects of the indirect DA agonist amphetamine (Hutchison
et al. 1999; Talledo et al. 2009), the effects of pramipexole
were not moderated by personality measures of novelty-
seeking, sensation-seeking, disinhibition, or extraversion;
unlike the PPI-modulatory effects of either amphetamine
(Swerdlow et al. 2003b; Talledo et al. 2009), direct D2/D3
agonists (Bitsios et al. 2005), or the NMDA antagonist/DA
releaser memantine (Swerdlow et al. 2009), these effects of
pramipexole were independent of baseline PPI levels.
The fact that pramipexole effects on PPI differ from
those of other DA agonists is consistent with preclinical
evidence in rats and humans. In rats, PPI-reducing effects
of pramipexole do not differ across strains that exhibit
pronounced differences in sensitivity to the PPI-disruptive
effects of amphetamine (Swerdlow et al. 2003b; Talledo et
al. 2009) and mixed D2/D3 agonists (Swerdlow et al. 2001,
2004a, b, c; Weber et al. 2008). Furthernore, unlike
amphetamine and mixed D2/D3 agonists, the PPI-
disruptive effects of pramipexole in rats are relatively
insensitive to selective D2 receptor blockade but are
opposed by compounds with selective functional antago-
nism at D3 receptors (Weber et al. 2009). Evidence for
differences in the PPI-modifying effects of pramipexole vs.
other DA agonists in humans comes from findings that
personality dimensions and/or baseline PPI moderate the
PPI-disruptive effects of amphetamine (Hutchison et al.
1999; Talledo et al. 2009) and mixed D2/D3 agonists
(Bitsios et al. 2005) but not those of pramipexole (present
study); this may suggest that these moderating effects
primarily reflect activity at D2 and not D3 DA receptors.
Pramipexole-induced PPI increases in humans were
limited to the 120-ms prepulse intervals. Reflex inhibition
at these longer intervals can be enhanced by attention
directed at a continuous prepulse (Filion et al. 1993). While
the present study utilized discrete (vs. continuous) prepulses
and no attentional instructions were given, it is nonetheless
possible that the mechanisms responsible for pramipexole’s
enhancement of “attentionally sensitive” inhibition reflect its
action on brain mechanisms that regulate attention. No
significant correlations were detected between increases in
Table 3 Peak reflex latency and habituation
0.125 mg group 0.1875 mg group
Placebo Active dose Placebo Active Dose
Prepulse Interval (ms) Peak startle latency (ms) [mean (SEM)]
0
a 60.9 (1.6) 61.4 (2.0) 63.5 (1.2) 62.1 (1.0)
10 56.9 (1.6) 58.3 (2.2) 59.7 (1.3) 59.3 (1.2)
20 55.9 (1.8) 56.7 (2.2) 59.7 (1.3) 58.5 (0.9)
30 54.2 (1.8) 55.9 (2.1) 56.6 (1.2) 57.4 (0.9)
60 52.5 (1.8) 54.0 (2.1) 54.0 (1.4) 54.9 (1.6)
120 57.2 (1.3) 56.9 (2.0) 58.6 (1.3) 59.1 (1.2)
Startle magnitude on pulse alone trials [mean (SEM)]
First block 117.2 (16.0) 116.7 (17.9) 145.9 (19.2) 144.6 (19.2)
Last block 81.6 (14.7) 73.1 (16.9) 87.8 (16.6) 92.5 (19.5)
aPulse alone trials
Fig. 4 Effects of pramipexole on startle magnitude (inset; mean±
SEM) and %PPI (mean±SEM) across all trial conditions in three
groups of rats administered placebo vs. 0.1 mg/kg pramipexole (n=8),
placebo vs. 0.3 mg/kg pramipexole (n=8) or placebo vs. 1.0 mg/kg
mg pramipexole (n=8). Open circle Placebo; closed circle active dose.
Insert, asterisk startle reducing effects of 1.0 mg/kg pramipexole (p<
0.035). Main figure, number sign PPI-enhancing effects of pramipex-
ole at 10–20-ms prepulse intervals for 0.1 and 0.3 mg/kg doses (p=
0.02); asterisk PPI-reducing effects of 0.3 and 1.0 mg/kg pramipexole
(p<−0.008–0.03)
696 Psychopharmacology (2009) 205:689–698self-rated drowsiness and PPI, but the present VAS
measures may not be adequately sensitive to detect
meaningful inter-individual differences in alertness and
are not designed to assess attentional states. In a recent
study with ten clinically normal adults, higher doses of
pramipexole (0.25–0.50 mg) caused sedation and im-
paired cognitive performance in sedation-sensitive tasks
(Hamidovic et al. 2008). However, because directed
attention is associated with higher PPI levels in normal
humans (Filion et al. 1993), it would be counter-intuitive
to explain the observed PPI increases based on attention-
impairing effects of pramipexole.
Confirmation that the present doses of pramipexole were
bioactive came from increases in self-rated drowsiness,
consistent with a number of reports with higher doses of
pramipexole (Samuels et al. 2006a, b; 2007; Hamidovic et
al. 2008). The lack of pramipexole effects on measures,
such as “queasiness” or “happiness,” and on autonomic
measures (e.g., pupil dilation), suggests that the doses in
this study were physiologically low (Samuels et al. 2006a,
b; 2007; Hamidovic et al. 2008) and raises the possibility
that different effects on PPI might have been detected at
higher doses. Such a prediction would be consistent with
the present study in rodents, which demonstrated an
inverted U dose function for pramipexole’s effects on PPI
(i.e., it increased PPI at low doses and reduced PPI at high
doses). Conceivably, low doses of pramipexole might
preferentially activate presynaptic receptors or a combina-
tion of pre- and post-synaptic receptors, making it difficult
to determine whether the observed increase in PPI reflected
functional decreases or increases in forebrain D3 stimula-
tion (Samuels et al. 2006b).
The nature of most studies using systemic drug
administration is that the precise mechanisms of drug
effects remain a matter of speculation. If we posit that the
PPI-enhancing effects of pramipexole in humans reflect
activation of post-synaptic forebrain D3 receptors, it would
be difficult to account for PPI deficits observed in
schizophrenia (Braff et al. 1978) or several other neuro-
psychiatric disorders (cf. Braff et al. 2001; Swerdlow et al.
2008) based solely on overactivity of D3 neurotransmis-
sion. On the other hand, if we posit that these effects of
pramipexole reflect its action at presynaptic DA receptors
that reduce forebrain DA “tone” (Samuels et al. 2006b),
then the observed increases in PPI might be loosely
consistent with PPI-enhancing effects of DA receptor
antagonists in previous reports (Swerdlow et al. 2006;
Vollenweider et al. 2006; Csomor et al. 2008). A strong
caveat to such a connection—between PPI-enhancement by
putative presynaptic effects of pramipexole and post-
synaptic receptor-blocking effects of antipsychotics—is that
these effects of antipsychotics are moderated by both
personality dimensions (Swerdlow et al. 2006) and baseline
PPI (Vollenweider et al. 2006; Csomor et al. 2008), neither
of which moderate the present effects of pramipexole.
Certainly, one might imagine that the PPI-enhancing effects
of drugs acting pre- vs. post-synaptically could both reflect
reduced DAergic “tone,” yet be moderated by different
biological factors. It is also conceivable that different
patterns of pramipexole effects might have emerged had
the 40 subjects in this study been stratified based on
different polymorphisms for the D3 receptor (Roussos et al.
2008a).
With the absence a clear understanding of whether the
present drug effects reflect pre- vs. post-synaptic actions of
pramipexole (or some combination thereof) and a lack of
genetic information on D3 receptor polymorphisms among
our subjects, we can still conclude from the present data
that: (1) D3 receptors do appear to regulate PPI in clinically
normal humans; (2) activation of these receptors by low
doses of pramipexole enhances long-interval PPI; and (3)
these effects appear to be independent of physiological
variables that moderate other forms of DAergic regulation
of PPI. It would be reasonable to consider whether such an
effect could be used as a basis for predicting therapeutic
sensitivity to D3 stimulation in clinical populations.
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